Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05308264 |
|
Recruitment Status :
Recruiting
First Posted : April 4, 2022
Last Update Posted : October 10, 2023
|
Sponsor:
Rigel Pharmaceuticals
Information provided by (Responsible Party):
Rigel Pharmaceuticals
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | May 2025 |
| Estimated Study Completion Date : | May 2025 |